‘Everyone Thinks Generics And Biosimilars Is Easy’ – Sandoz’s Saynor Talks Evolution Of Core Businesses
Asserts Importance Of Small-Molecule Generics As Biosimilars Are On The Rise
In the second part of our exclusive interview with Richard Saynor, the Sandoz CEO discusses the importance of both the small-molecule generics and biosimilars businesses for the company, talking about portfolio selection and specific product opportunities for biosimilars while also contrasting the firm’s European and US generics leadership aspirations and approaches to the business.
